Magic Sleeping Peptide DSIP in Our Life -By Polypeptide.ltd
DSIP Peptide Structure
Authoritative source：PubChem
Introduuction Delta-sleep-inducing peptide (DSIP, other name: Emideltide; DSIP nonapeptide; Deltaran) is a naturally occurring short peptide with various physiological and endocrine functions. Its name derives from its ability to induce sleep in rabbits and its initial discovery in 1977 from rat brains during slow-wave sleep. As researchers continue to explore DSIP, they are uncovering its diverse roles. Currently, it is known that DSIP can modulate corticotropin levels, inhibit somatostatin secretion, reduce stress, normalize blood pressure, regulate sleep patterns, and influence pain perception. Moreover, DSIP holds potential for future applications in cancer treatment, depression management, and prevention of free radical damage.
Full form of DSIP in medical terms DSIP (Delta-sleep-inducing peptide) is a neuropeptide that when infused into the mesodiencephalic
Custom Synthesis Peptide Manufacturers
https://www.polypeptide.ltd/
ventricle of recipient rabbits induces spindle and delta EEG activity and reduced motor activities. DSIP is a neuropeptide consisting of nine amino acids with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE). It was first discovered in 1974 and has since been extensively studied for its various physiological functions.
Machinism of DSIP DSIP (Delta-sleep-inducing Peptide) is a peptide that exerts its effects by interacting with receptors in the brain that are associated with sleep and relaxation. Its primary mechanism of action is believed to involve the modulation of the GABAergic system, which plays a key role in promoting relaxation and sleep. Here's a more detailed explanation of how DSIP works: ❶ Binding to Receptors. DSIP binds to specific receptors in the brain that are involved in sleep regulation. While the exact receptors it binds to are not fully determined, it is thought to interact with GABA receptors and possibly other neurotransmitter receptors. ❷ Increased GABA Production. Upon binding to its receptors, DSIP may increase the production or release of the neurotransmitter gamma-aminobutyric acid (GABA). GABA is an inhibitory neurotransmitter, meaning it reduces neuronal excitability and slows down brain activity. This leads to a state of relaxation and helps induce sleep. ❸ Sleep Promotion. By increasing GABA levels, DSIP helps to promote sleep, particularly non-REM sleep. Non-REM sleep includes stages of deep sleep, which are essential for physical and mental restoration and are associated with memory consolidation and overall well-being. ❹ Impact on Circadian Rhythms. DSIP has been shown to interact with other signaling molecules, such as serotonin and melatonin, which are involved in regulating circadian rhythms. This interaction may play a role in enhancing the synchronization of the sleep-wake cycle. ❺ Stress-Reduction. DSIP's stress-protective action may also contribute to its sleep-promoting effects. By reducing stress-induced metabolic and functional disorders, it can help create a more conducive environment for sleep. It's important to note that while DSIP has shown promising sleep-inducing effects in various studies, the full extent of its mechanism of action and its interaction with different neurotransmitter systems
Custom Synthesis Peptide Manufacturers
https://www.polypeptide.ltd/
and receptors in the brain is not yet fully understood. Further research is needed to gain a comprehensive understanding of DSIP's functions and potential therapeutic applications.
Benefits of DSIP The benefits of DSIP (Delta-sleep-inducing Peptide) are wide-ranging and diverse, as supported by scientific research. Some of the notable benefits and roles of DSIP include: ❶ Sleep Promotion. DSIP is a sleep-promoting substance that can help improve sleep quality and duration. It has a modulating effect on sleep and wake functions, making it particularly effective in circumstances where sleep is disturbed.
Authoritative source：Wiki ❷ Stress Reduction. DSIP acts as a stress-limiting factor and exhibits anti-stress properties, helping to alleviate stress-induced metabolic and functional disorders. ❸ Endocrine Regulation. DSIP affects various hormonal levels, including decreasing basal corticotropin levels and blocking its release, stimulating luteinizing hormone (LH) secretion, and affecting somatoliberin and somatotrophin secretion. ❹ Neuroprotective Effects. DSIP has demonstrated neuroprotective properties, protecting the brain from various insults and potential damage. ❺ Antioxidant Properties. DSIP has been shown to enhance oxidative phosphorylation in rat mitochondria, suggesting potential antioxidant effects.
Custom Synthesis Peptide Manufacturers
https://www.polypeptide.ltd/
❻ Geroprotective Effects. DSIP has been found to have geroprotective effects, slowing down age-related changes and contributing to increased maximum life span in certain studies. Additionall, DSIP has been found to have several other physiological effects. ❶ Potential for Addiction and Withdrawal Treatment. DSIP may act antagonistically on opiate receptors, inhibiting the development of opioid and alcohol dependence and showing promise in clinical trials for treating withdrawal syndromes. ❷ Immune Function. DSIP may play a role in immune function, though further research is needed to fully understand its impact. ❸ Potential Therapeutic Applications. DSIP has been investigated for its use in various medical conditions, including narcolepsy, chronic pain, major depressive disorder, Alzheimer's disease, and central nervous system function in children after antiblastomic therapy.
Side effects of Delta-sleep-inducing peptide The safety and long-term effects of Delta-sleep-inducing peptide (DSIP) have not been extensively studied in clinical research, so caution is advised when using this peptide. Reported side effects of DSIP use are relatively rare, but they may include: • Headache • Hypotension (Low Blood Pressure) • Vagal reactions (dizziness, ringing ears, and sweating) • Vomiting Since the long-term effects of DSIP use are not well-understood, it is essential to exercise caution and use this peptide under proper medical supervision. If you experience severe or persistent side effects while using DSIP, it is recommended to discontinue its use immediately and consult a healthcare professional for further evaluation.
Dosage of DSIP For the suggested dosage, inject 0.1mL subcutaneously once daily at bedtime.
Custom Synthesis Peptide Manufacturers
https://www.polypeptide.ltd/
Authoritative source：Wiki As with any experimental or alternative treatment, it's essential to consult a qualified healthcare professional before using DSIP or any other peptide-based therapy. They can assess your individual health status, provide personalized advice, and ensure proper dosing and monitoring if DSIP is deemed appropriate for your specific situation.
Is DSIP peptide safe? The safety of DSIP (Delta-sleep-inducing Peptide) has not been extensively studied in large-scale clinical trials, and its long-term effects in humans are not well-established. As of my knowledge cutoff in September 2021, there have been limited clinical studies on DSIP in humans, and it is not widely approved or regulated for medical use by health authorities like the FDA (U.S. Food and Drug Administration). While DSIP has shown promising results in certain research studies, it's essential to approach its use with caution and under proper medical supervision. Some points to consider regarding DSIP's safety include: ❶ Limited Research. As a peptide used for specific medical purposes, DSIP has not undergone the same rigorous testing and evaluation as approved medications. ❷ Individual Variability. Peptides can have varying effects on individuals, and responses may differ depending on factors such as age, health status, and medical history. ❸ Lack of Regulation. DSIP may be available from various sources, but its production and quality control might not be regulated, potentially leading to variations in product potency and purity.
Custom Synthesis Peptide Manufacturers
https://www.polypeptide.ltd/
❹ Long-Term Effects. The long-term effects of DSIP use in humans are not well-documented, and its safety profile over extended periods is not fully understood. ❺ Interaction with Other Medications. DSIP's interactions with other medications or health conditions have not been thoroughly studied. Ultimately, the safety and efficacy of DSIP and similar peptides will require more comprehensive research and clinical trials to establish their place in medical practice and to determine their long-term effects. Until then, it's crucial to prioritize evidence-based and approved treatments for sleep-related issues and other medical conditions.
Reference citations [1] Bjartell A, Ekman R, Sundler F, Widerlöv E (1988). "Delta sleep-inducing peptide (DSIP): An overview of central actions and possible relationship to psychiatric illnesses". Nordic Journal of Psychiatry. 42 (2): 111–117. doi:10.3109/08039488809103215. [2] Charnay Y, Bouras C, Vallet PG, Golaz J, Guntern R, Constantinidis J (1989). "Immunohistochemical distribution of delta sleep inducing peptide in the rabbit brain and hypophysis". Neuroendocrinology. 49 (2): 169–175. doi:10.1159/000125110. PMID 2657475. [3] Graf MV, Hunter CA, Kastin AJ (1984). "Presence of Delta-Sleep-Inducing Peptide-Like Material in Human Milk". Journal of Clinical Endocrinology & Metabolism. 59 (1): 127–32. doi:10.1210/jcem-59-1-127. PMID 6547144. [4] Gimble JM, Ptitsyn AA, Goh BC, Hebert T, Yu G, Wu X, Zvonic S, Shi XM, Floyd ZE (2009). "Delta sleep-inducing peptide and glucocorticoidinduced leucine zipper: potential links between circadian mechanisms and obesity?". Obesity Reviews. 10: 46–51. doi:10.1111/j.1467-789X.2009.00661.x. PMID 19849801. S2CID 5943377. [5] Iyer KS, McCann SM (November 1987). "Delta sleep inducing peptide (DSIP) stimulates the release of LH but not FSH via a hypothalamic site of action in the rat". Brain Research Bulletin. 19 (5): 535–538. doi:10.1016/0361-9230(87)90069-4. PMID 3121137. S2CID 7710977. [6] Khvatova EM, Samartzev VN, Zagoskin PP, Prudchenko IA, Mikhaleva II (2003). "Delta sleep inducing peptide (DSIP): effect on respiration activity in rat brain mitochondria and stress protective
Custom Synthesis Peptide Manufacturers
https://www.polypeptide.ltd/
potency under experimental hypoxia". Peptides. 24 doi:10.1016/S0196-9781(03)00040-8. PMID 12668217. S2CID 23492463.
(2):
307–311.
[7] Koval'zon VM (1994). "[DSIP: the sleep peptide or an unknown hypothalamic hormone?]". Zhurnal Evoliutsionnoi Biokhimii I Fiziologii (in Russian). 30 (2): 310–319. PMID 7817664.: Koval'zon VM (1994). "[DSIP: the sleep peptide or an unknown hypothalamic hormone?]". Zhurnal Evoliutsionnoi Biokhimii I Fiziologii (in Russian). 30 (2): 310–319. PMID 7817664. [8] Monnier M, Dudler L, Gächter R, Maier PF, Tobler HJ, Schoenenberger GA (April 1977). "The delta sleep inducing peptide (DSIP). Comparative properties of the original and synthetic nonapeptide". Experientia. 33 (4): 548–52. doi:10.1007/BF01922266. PMID 862769. S2CID 33287951. [9] Popovich IG, Voitenkov BO, Anisimov VN, Ivanov VT, Mikhaleva II, Zabezhinski MA, Alimova IN, Baturin DA, Zavarzina NY, Rosenfeld SV, Semenchenko AV, Yashin AI (2003). "Effect of delta-sleep inducing peptide-containing preparation Deltaran on biomarkers of aging, life span and spontaneous tumor incidence in female SHR mice". Mechanisms of Ageing and Development. 124 (6): 721–731. doi:10.1016/S0047-6374(03)00082-4. PMID 12782416. S2CID 12666819. [10] Pollard BJ, Pomfrett CJ (2001). "Delta sleep-inducing peptide". Eur. J. Anaesthesiol. 18 (7): 419–422. doi:10.1046/j.1365-2346.2001.00917.x. PMID 11437870. [11] Sudakova KV, Coghlan JP, Kotov AV, Salieva RM, Polyntsev YV, Koplik EV (1995). "Delta-sleep inducing peptide sequels in mechanisms of resistance to emotional stress". Annals of the New York Academy of Sciences. 771 (1): 240–251. Bibcode:1995NYASA.771..240S. doi:10.1111/j.1749-6632.1995.tb44685.x. PMID 8597403. S2CID 40317428. [12] Schoenenberger GA, Maier PF, Tobler HJ, Monnier M (1977). "A naturally occurring delta-EEG enhancing nonapeptide in rabbits". European Journal of Physiology. 369 (2): 99–109. doi:10.1007/BF00591565. PMID 560681. S2CID 8845219. [13] Stanojilovic OP, Zivanovic DP, Su Sic VT (2002). "The effects of Delta Sleep-Inducing Peptide on incidence and severity in metaphit-induced epilepsy in rats". Pharmacological Research. 45 (3): 241–247. doi:10.1006/phrs.2001.0938. PMID 11884222. [14] Stanojlović O, Zivanović D, Mirković S, Mikhaleva I (February 2004). "Delta sleep-inducing peptide and its tetrapeptide analogue alleviate severity of metaphit seizures". Pharmacol. Biochem. Behav. 77 (2): 227–34. doi:10.1016/j.pbb.2003.10.014. PMID 14751449. S2CID 25447645.
Custom Synthesis Peptide Manufacturers
https://www.polypeptide.ltd/
[15] Sinyukhin AB, Timoshinov GP, Komilov VA, Shabanov PD (2009). "Delta sleep-inducing peptide analogue corrects the eNS functional state of children treated with antiblastomic therapy". European Neuropsychopharmacology. 19: S681–S682. doi:10.1016/S0924-977X(09)71101-0. S2CID 54240550. [16] Schneider-Helmert D (1986). "DSIP in Sleep Disturbances". Eur Neurol. 25 (2): 154–157. doi:10.1159/000116097. PMID 3758119. [17] Schneider-Helmert D, Schoenenberger GA (1981). "The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep". Cellular and Molecular Life Sciences. 37 (9): 913–917. doi:10.1007/BF01971753. PMID 7028502. S2CID 33195794. [18] Yukhananov RY, Tennila TM, Miroshnichenko II, Kudrina VS, Ushakov AN, Melnik EI (1992). "Ethanol and Delta Sleep Inducing Peptide effects on brain monoamines". Pharmacol. Biochem. Behav. 43 (3): 683–687. doi:10.1016/0091-3057(92)90396-W. PMID 1448465. S2CID 54364363.
Custom Synthesis Peptide Manufacturers
https://www.polypeptide.ltd/